Dose finding with continuous outcome in phase I oncology trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose finding with continuous outcome in phase I oncology trials

Published:2014-11-19 Issue:2 Volume:14 Page:102-107
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Wang Yunfei¹,Ivanova Anastasia¹

Affiliation:

1. Department of Biostatistics; The University of North Carolina at Chapel Hill; Chapel Hill NC 27599-7420 USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1662/fullpdf

Reference24 articles.

1. Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs;Penel;Invest New Drugs,2011

2. Dose escalation methods in phase I cancer clinical trials;Le Tourneau;Journal of the National Cancer Institute,2009

3. Phase I study of the poly(ADP-ribose) polymerase inhibitor AG014699 in combination with temozolomide in patients with advanced solid tumors;Plummer;Clinical Cancer Research,2008

4. Dose-finding based on multiple toxicities in a soft tissue sarcoma trial;Bekele;Journal of the American Statistical Association,2004

5. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in phase I clinical trials;Chen;Contemporary Clinical Trials,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials;Trials;2023-11-21

2. CRM and partial order CRM with adaptive rescaling for dose‐finding in immunotherapy trials with a continuous outcome;Statistics in Medicine;2023-04-03

3. A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints;Biometrical Journal;2019-07-12

4. A benchmark for dose finding studies with continuous outcomes;Biostatistics;2018-08-24

5. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent;Clinical Trials;2018-05-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3